CoChat

Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics

Open access
Calles-Escandón, Jorge, Lovato, Laura C., Simons-Morton, Denise G., Kendall, David M., Pop-Busui, Rodica, Cohen, Robert M., Bonds, Denise E., Fonseca, Vivian A., Ismail-Beigi, Faramarz, Banerji, Mary Ann, Failor, Alan, Hamilton, Bruce · 2010 · Diabetes Care

The DOI matches its Crossref record, with a small difference in title or year; 27 of the 28 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine if baseline subgroups in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial can be identified for whom intensive compared with standard glycemia treatment had different effects on all-cause mortality. RESEARCH DESIGN AND METHODS: Exploratory post hoc intention-to-treat comparisons were made between intensive and standard glycemia groups on all-cause mortality by subgroups defined by baseline characteristics. RESULTS: There were few significant interactions between baseline characteristics and effects of intensive versus standard glycemia treatment on mortality: self-reported history of neuropathy (hazard ratio [HR] 1.95, 95% CI 1.41–2.69) versus no history of neuropathy (0.99, 0.79–1.26; P value for interaction 0.0008), higher A1C (A1C >8.5%: HR 1.64, 95% CI 1.22–2.22; A1C 7.5–8.4%: 1.00, 0.75–1.34; A1C <7.5%: 1.00, 0.67–1.50; P value for interaction 0.04), and aspirin use (HR 1.45, 95% CI 1.13–1.85, compared with 0.96, 0.72–1.27, in nonusers; P value for interaction 0.03). CONCLUSIONS: We found a remarkable similarity of effect from intensive compared with standard glycemia treatment on mortality across most baseline subgroups. No differential effect was found in subgroups defined by variables anticipated to have an interaction: age, duration of diabetes, and previous history of cardiovascular disease. The three baseline characteristics that defined subgroups for which there was a differential effect on mortality may help identify patients with type 2 diabetes at higher risk of mortality from intensive regimens for glycemic control. Further research is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc09-1471

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Demographic characteristics and medical history. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within demographic and medical history subgroups, adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
Figure 1 Demographic characteristics and medical history. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within demographic and medical history subgroups, adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.CC BY-NC-ND · PubMed Central
Figure 2 Medication and laboratory tests. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within the medication and laboratory tests subgroups adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.
Figure 2 Medication and laboratory tests. HRs are shown for all-cause mortality in intensive versus standard glycemia groups within the medication and laboratory tests subgroups adjusted for the study stratification factors: 1) history of CVD (except for the analysis of CVD variables), 2) assignment to the Lipid or Blood Pressure trial (each trial had different eligibility criteria), 3) assignment to Lipid trial and randomized to fenofibrate, and 4) assignment to the Blood Pressure trial and randomized to the intensive blood pressure intervention.CC BY-NC-ND · PubMed Central
Figure 3 A1C and all-cause mortality. Spline curves displaying the log of the HR for all-cause mortality by treatment and baseline A1C are shown. All HRs are with respect to standard glycemia with baseline A1C of 7.0. The bold line represents the intensive treatment group, the finer line the standard group, and the colored lines the 95% CIs.
Figure 3 A1C and all-cause mortality. Spline curves displaying the log of the HR for all-cause mortality by treatment and baseline A1C are shown. All HRs are with respect to standard glycemia with baseline A1C of 7.0. The bold line represents the intensive treatment group, the finer line the standard group, and the colored lines the 95% CIs.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 160

Metadata

Authors
Calles-Escandón, J., Lovato, L. C., Simons-Morton, D. G., Kendall, D. M., Pop-Busui, R., Cohen, R. M., Bonds, D. E., Fonseca, V. A., Ismail-Beigi, F., Banerji, M. A., Failor, A., & Hamilton, B.
Affiliations
  • Wake Forest University Health Sciences (US)
  • National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland;
  • Park Nicollet Health Services (US)
  • Department of Endocrinology, Metabolism, and Nutrition, University of Michigan Medical School, Ann Arbor, Michigan;
  • University of Cincinnati Medical Center (US)
  • National Institutes of Health (US)
  • Tulane University (US)
  • VA Medical Center, Section of Endocrinology, University of Cleveland, Cleveland, Ohio;
  • State University of New York (US)
  • University of Washington (US)
  • University of Maryland, Baltimore (US)
Corresponding author
Calles-Escandón, Jorge
Venue
Diabetes Care
Published
2010-01-26
Volume
33
Issue
4
Pages
721-727
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2136749671
Cited by
160
References
28
Citations by year
2026: 1 · 2024: 5 · 2023: 6 · 2022: 3 · 2021: 6 · 2020: 13 · 2019: 3 · 2018: 7 · 2017: 5 · 2016: 14 · 2015: 20 · 2014: 22 · 2013: 13 · 2012: 10
FWCI
13.27
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
tight glycemic control, type 2 diabetes, all-cause mortality, subgroup analysis, HbA1c, aspirin use, cardiovascular risk, ACCORD trial, treatment effect heterogeneity
MeSH terms
Aged, Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.